Off-label dermatologic uses of IL-23 inhibitors
Background While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels. The purpose of this review is to summarize and i...
Shranjeno v:
| Principais autores: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis Group
2024-12-01
|
| Serija: | Journal of Dermatological Treatment |
| Teme: | |
| Online dostop: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2436015 |
| Oznake: |
Brez oznak, prvi označite!
|